ストックスクリーナーアプリを入手
86.35
0.86%
0.995
前日終値:
$85.36
開ける：
$84.75
24時間の取引高:
464.32K
Relative Volume:
0.10
時価総額：
$32.62B
収益：
$4.82B
当期純損益:
$930.40M
株価収益率:
36.93
EPS:
2.3381
ネットキャッシュフロー:
$1.43B
1週間 パフォーマンス:
-0.68%
1か月 パフォーマンス:
-2.06%
6か月 パフォーマンス:
+38.36%
1年 パフォーマンス:
+28.40%
1日の値動き範囲:
$84.75
$86.52
1週間の範囲:
$84.75
$87.70
52週間の値動き範囲:
$54.11
$92.59
Dexcom Inc Stock (DXCM) Company Profile
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
86.44 | 32.69B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
100.10 | 168.71B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
87.91 | 110.49B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
284.30 | 105.65B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.98 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.09 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2026-01-12 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-12-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 開始されました | Evercore ISI | In-line |
| 2025-10-21 | 再開されました | Stifel | Buy |
| 2025-09-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 開始されました | Argus | Buy |
| 2025-06-16 | 開始されました | Truist | Buy |
| 2025-05-30 | 開始されました | Goldman | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
| 2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2023-01-26 | 開始されました | Wolfe Research | Outperform |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-15 | 開始されました | Bernstein | Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2021-01-06 | アップグレード | UBS | Neutral → Buy |
| 2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
| 2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-10-23 | 開始されました | Stifel | Buy |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
| 2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-04 | 開始されました | Goldman | Sell |
| 2018-04-04 | 開始されました | Guggenheim | Neutral |
| 2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia - GlobeNewswire Inc.
RBC Raises Price Target on DexCom to $105 From $90, Keeps Outperform Rating - marketscreener.com
Behavioral Patterns of DXCM and Institutional Flows - Stock Traders Daily
Under a preset trading plan, DexCom (DXCM) EVP Sadie Stern sells 2,565 shares. - Stock Titan
Dexcom stock last trades at USD 86.68 on September 28, 2026 - AD HOC NEWS
Why DexCom Could Be the Big Winner Out of Oura’s IPO - Barron's
Dexcom Data Points to a CGM Awareness Gap, and Room to Grow - Medical Product Outsourcing
The Insider Report: The Leaders Have Taken Off - Benzinga
DexCom stock reports 13.1 percent revenue growth at USD 86.62 - AD HOC NEWS
Dexcom Publishes New Report During Easd 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care - marketscreener.com
Tandem Diabetes Expands Insulin Delivery System to 12 New Countries - marketscreener.com
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care - The Joplin Globe
Dexcom stock slips 2.01 percent ahead of the open - AD HOC NEWS
DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow - Yahoo Finance
DexCom stock trades below its 52-week high as Truist lifts target - AD HOC NEWS
DexCom, Inc. (DXCM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced? - finance.yahoo.com
Dexcom stock falls 1.1 percent ahead of the open - AD HOC NEWS
DexCom, Inc. (DXCM) latest stock news and headlines - Yahoo Finance UK
DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer - Yahoo Finance
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
GlucoGuard, a Division of American Diversified Holdings (ADHC), Has Completed an Investors Deck Focused on Funding Research Required for FDA Approval - ACCESS Newswire
American Diversified Holdings Corporation (ADHC) Seeks Funding; Advances Dexcom App Integration - TradingView
Dexcom stock holds near its yearly high after Q2 growth - AD HOC NEWS
Dexcom stock heads into the open after Nasdaq gains 0.45 percent - AD HOC NEWS
Dexcom Inc. stock gains on strong Q2 2026 growth and solid diabetes-tech momentum - AD HOC NEWS
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings and Promising Growth in the Medical Device Sector - directorstalkinterviews.com
Dexcom stock heads into the open after a 1.61 percent gain - ad-hoc-news.de
Dexcom Inc. stock gains on leadership change and strong recent performance - AD HOC NEWS
Dexcom Inc. stock gains on fresh Truist and TD Cowen price targets - AD HOC NEWS
What Has Put DexCom (DXCM) Back in Focus? - Kalkine Media
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DXCM Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus
TD Cowen reiterates Buy rating on DexCom, $95 price target - TradingView
Dexcom Inc. stock gains as insider sales and valuation come into focus - ad-hoc-news.de
Dexcom stock heads into the open after a 0.68% Nasdaq gain - AD HOC NEWS
Dexcom Inc. stock edges higher as Truist Securities reiterates Buy rating - AD HOC NEWS
Truist Securities Adjusts DexCom Price Target to $102 From $93, Maintains Buy Rating - marketscreener.com
Dexcom stock heads into the open after a 1.0% gain - AD HOC NEWS
Dexcom Insider Sold Shares Worth $679,769, According to a Recent SEC Filing - marketscreener.com
Dexcom (NASDAQ: DXCM) director’s trust sells 8,089 shares in preset plan - Stock Titan
Dexcom (NASDAQ: DXCM) legal chief sells shares, keeps 99,885-share stake - Stock Titan
DexCom Inc (DXCM): GF Score of 95 Signals Strong Outperformance Potential - GuruFocus
Dexcom gives CFO Jereme Sylvain expanded role - MedTech Dive
Dexcom, Inc. Announces Appointment of Jereme Sylvain as Executive Vice President and Chief Operating Officer, Effective September 14, 2026 - marketscreener.com
Dexcom Promotes Jereme Sylvain to Chief Operating Officer - Yahoo Finance
Dexcom (DXCM) CFO trades stock under preset plan - Stock Titan
DexCom | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
DexCom Inc Share PriceDXCM, RNS News, Articles, Quotes, & Charts (NASDAQ:DXCM) - Proactive financial news
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dexcom appoints Glenn Boehnlein to board of directors - The Globe and Mail
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
0.50%
大文字化:
|
ボリューム (24 時間):